Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Breast Cancer: Page 4
At-home test spots biomarkers related to breast abnormalities
By
LabPulse.com staff writers
Namida Lab has developed the Auria diagnostic test, which provides a personalized score and classification that corresponds to an urgency level, indicating when a mammogram should be scheduled. The laboratory-developed test is available to women between the ages of 33 and 85 with an average risk of developing breast cancer, regardless of their breast tissue density.
September 13, 2022
Natera presents colorectal, breast cancer data at ESMO 2022
By
LabPulse.com staff writers
One abstract, related to the Bellini trial, examined the potential clinical utility of circulating tumor DNA (ctDNA) in assessing the response to neoadjuvant immunotherapy in patients with early-stage (I-II) triple-negative breast cancer (TNBC).
September 12, 2022
Ibex announces study results for breast pathology platform
By
LabPulse.com staff writers
Ibex chief medical officer Dr. Judith Sandbank reported at the congress 100% sensitivity and specificity for pathologists diagnosing breast cancer using the platform.
September 8, 2022
cfDNA detection may simplify breast cancer monitoring: study
By
Jared Berberabe
In a study published recently in Science Advances, the researchers found that plasma cell-free DNA (cfDNA) contains high resolution, genome-wide binding estrogen receptors (ER) and FOXA1 profiles for breast cancer.
August 30, 2022
FDA clears Angle’s Parsortix breast cancer system
By
LabPulse.com staff writers
The FDA clearance is the first FDA product clearance to harvest cancer cells from a blood sample for subsequent analysis. This offers the prospect of a new era of personalized cancer care, according to the company.
July 27, 2022
Clinics begin adopting Genetic Technologies risk test
By
LabPulse.com staff writers
The clinics can focus on testing for a single disease or multiple diseases, including breast cancer, colorectal cancer, ovarian cancer, coronary artery disease, prostate cancer, and type 2 diabetes, the company said.
June 30, 2022
Artemis signs $250M deal for liquid biopsy tests with Datar
By
LabPulse.com staff writers
The contract gives Artemis DNA the exclusivity to commercialize and distribute the liquid biopsy tests Trucheck Pragma and Cancertrack in the U.S. and Vietnam. Trucheck Pragma is a noninvasive blood-based screening test for lung, stomach, colon, pancreas, prostate, breast, and ovarian cancers; Cancertrack is a cancer monitoring test that allows patients to evaluate response/resistance during treatment and monitor recurrence of cancer.
May 15, 2022
Veracyte touts gene expression study data at ESMO meeting
By
LabPulse.com staff writers
To generate consensus regarding the clinical utility in breast cancer treatment of GEP tests, including Veracyte's Prosigna breast cancer assay, 133 specialists from 11 European countries were surveyed in the PROCURE study.
May 3, 2022
Agendia highlights presentations at ESMO Breast Cancer 2022
By
LabPulse.com staff writers
The first poster presentation concluded that the next-generation sequencing versions of MammaPrint and BluePrint are equivalent to a centralized microarray test, according to the vendor.
May 3, 2022
Natera highlights Signatera data at AACR
By
LabPulse.com staff writers
One study focuses on circulating tumor DNA (ctDNA) prognosis in adjuvant triple-negative breast cancer. Researchers found that 19.9% of patients with early-stage disease were found to have detectable ctDNA after surgery (which was strongly associated with poorer outcomes), and that lead time between first ctDNA positivity and recurrence on imaging was a median of six months.
April 10, 2022
Paige receives marks for breast lymph node AI software
By
LabPulse.com staff writers
The AI medical device software helps pathologists detect if breast cancer has metastasized to lymph nodes along with review by pathologists.
April 7, 2022
AACR announces 2022 cancer research award recipients
By
LabPulse.com staff writers
The award recognizes female researchers who have made pioneering contributions to the understanding and treatment of breast and gynecological cancer. This year's awardees include:
April 3, 2022
Previous Page
Page 4 of 12
Next Page